ClinicalTrials.gg

Program

verducatib

Also written as “BI 1291583”, “Verducatib” and “BI 1291583 mixed with [C-14] BI 1291583”.

In Boehringer Ingelheim's pipeline, DPP1/CatC inhibitor. Its studies are mostly in Bronchiectasis · Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis, led by Boehringer Ingelheim.

Furthest: phase 3, since Mar 7, 202521 company-led studies, 7 open or runningNext primary completion: Dec 14, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim217 open or runningphase 3since Mar 7, 2025Jan 22, 2018Dec 14, 2026phase 1 · NCT07781631
  • Named in Boehringer Ingelheim’s own pipeline as Verducatib (BI 1291583), phase 3, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jan 22, 2018.

  1. Dec 22, 2021Phase 1 study in HealthyNCT05183347 · 36 enrolled · Japan
  2. Feb 3, 2022Phase 2 study in BronchiectasisNCT05238675 · 322 enrolled · United States, Australia, Belgium and more
  3. Apr 17, 2023Phase 1 study in HealthyNCT05833035 · 8 enrolled · Netherlands
  4. Apr 26, 2023Phase 2 study in BronchiectasisNCT05846230 · 268 enrolled · United States, Australia, Belgium and more
  5. May 10, 2023Phase 2 study in Cystic FibrosisNCT05865886 · 22 enrolled · United States, Belgium, France and more
  6. Dec 4, 2023Phase 1 study in HealthyNCT06166992 · 14 enrolled · Netherlands
  7. Oct 7, 2024Phase 1 study in HealthyNCT06631417 · 30 enrolled · Germany
  8. Jan 20, 2025Phase 1 study in HealthyNCT06791187 · 14 enrolled · Germany
  9. Mar 7, 2025Phase 3 study in BronchiectasisNCT06872892 · 1,755 planned · United States, Argentina, Australia and more
  10. Apr 7, 2025Phase 1 study in HealthyNCT06917872 · 20 enrolled · Germany
  11. Jun 10, 2025Phase 1 study in HealthyNCT07023354 · 32 planned · United States
  12. Apr 9, 2026Phase 1 study in HealthyNCT07531628 · 12 enrolled · China
  13. Aug 7, 20262 phase 1 studies in HealthyNCT07760246, NCT07781631
  14. Oct 23, 20262 phase 3 studiesNCT07907991, NCT07915219

Ahead

  1. Dec 14, 2026Primary completion: phase 1 study in HealthyNCT07781631
  2. Dec 23, 2026Primary completion: phase 1 study in HealthyNCT07023354
  3. Dec 30, 2026Primary completion: phase 1 study in HealthyNCT07760246
  4. Mar 31, 2027Primary completion: phase 2 study in BronchiectasisNCT05846230

TargetBeta

“DPP1/CatC inhibitor”the company's pipeline, read by Claude · source

Other programs on CTSC

ProgramCompanyFurthest phaseStudies
brensocatibruleInsmedphase 317
RSS0343Jiangsu HengRui Medicinephase 24

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07915219Bronchiectasis · United States, Argentina, Austria and more3Not yet recruitingJul 31, 20291,500
NCT07907991Pulmonary Disease, Chronic Obstructive · United States, Italy, Malaysia3Not yet recruitingNov 12, 20291,800
NCT07781631Healthy · Germany1RecruitingDec 14, 202620
NCT07760246Healthy · Germany1Active, not recruitingDec 30, 202656
NCT07531628Healthy · China1CompletedJul 14, 202612
NCT07023354Healthy · United States1RecruitingDec 23, 202632
NCT06917872Healthy · Germany1CompletedSep 9, 202520
NCT06872892Bronchiectasis · United States, Argentina, Australia and more3RecruitingJun 15, 20271,755
NCT06791187Healthy · Germany1CompletedFeb 21, 202514
NCT06631417Healthy · Germany1CompletedJan 10, 202530
NCT06166992Healthy · Netherlands1CompletedFeb 7, 202414
NCT05865886Cystic Fibrosis · United States, Belgium, France and more2CompletedOct 7, 202422
NCT05846230Bronchiectasis · United States, Australia, Belgium and more2Active, not recruitingMar 31, 2027268
NCT05833035Healthy · Netherlands1CompletedJul 5, 20238
NCT05238675Bronchiectasis · United States, Australia, Belgium and more2CompletedMay 1, 2024322
NCT05183347Healthy · Japan1CompletedJul 27, 202236
NCT04866160Healthy · Germany1CompletedNov 30, 202124
NCT03890887Healthy · Germany1CompletedJul 29, 201914
NCT03868540Healthy · Germany1TerminatedNov 25, 201924
NCT03837964Healthy · Germany1CompletedApr 24, 201912
NCT03414008Healthy · Germany1TerminatedNov 18, 201954

How it is read

Names in the registry

  • “BI 1291583”, 17 entries
  • “Verducatib”, 4 entries
  • “verducatib”, 1 entry
  • “BI 1291583 mixed with [C-14] BI 1291583”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.